Ready-to-use vaccine and antibody plans for new virus threats
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats
This project builds plug-and-play vaccine and antibody designs to speed protection for people against newly emerging RNA viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11180133 on NIH RePORTER |
What this research studies
Researchers from universities, government, and industry are working together to create reusable vaccine and therapeutic antibody blueprints for several families of enveloped RNA viruses. They will use lab experiments and animal models to refine vaccine parts, engineer better antigens, and test two RNA vaccine platforms and antibody therapies for immune response and safety. The team will share tools across projects, focus on manufacturability, and plan regulatory pathways so products can move toward human use more quickly. The goal is to have ready designs that can be rapidly adapted and deployed if a new viral threat appears.
Who could benefit from this research
Good fit: People at risk of infection from the targeted virus families (Nairoviridae, Hantaviridae, or Paramyxoviridae) or volunteers for future early-stage vaccine or antibody trials would be the most relevant candidates.
Not a fit: Patients with conditions unrelated to the targeted emerging viruses are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could shorten the time to deliver effective vaccines and antibody treatments during new viral outbreaks, reducing illness and saving lives.
How similar studies have performed: RNA vaccine and monoclonal antibody approaches have shown clear success in real-world outbreaks (for example COVID-19), but applying standardized plug-and-play blueprints across many different emerging viruses is a newer and partly untested strategy.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Chandran, Kartik — Albert Einstein College of Medicine
- Study coordinator: Chandran, Kartik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.